Among adults who regained at least 10% of their post-bariatric surgery weight loss, GLP-1 receptor agonist users recovered nearly twice as much of that regained weight compared to non-users — 14.8% versus 8.1% of recurrent weight lost at 12 months (p=0.017), with a similarly significant advantage at 6 months (9.6% vs. 4.3%, p=0.005). The retrospective cohort drew from the OneFlorida+ Data Trust (2015–2024), matching 72 GLP-1 RA users against 139 non-users at the 12-month mark, with inverse probability weighting applied to reduce confounding. Crucially, no elevated risk of gastrointestinal or post-surgical adverse events was detected.
Weight recurrence affects an estimated 20–30% of bariatric surgery patients within five years and remains one of the field's most vexing clinical gaps. This real-world dataset addresses a population historically excluded from GLP-1 RA trials, where altered gut anatomy and hormonal signaling post-surgery could theoretically modify drug response or safety. The finding that these agents appear both effective and safe in this cohort is clinically meaningful — but the sample size is notably small (fewer than 75 users per timepoint), limiting statistical power and generalizability. The retrospective, observational design precludes causal inference, and medication adherence data are absent. Still, for clinicians managing post-bariatric weight regain with few evidence-based pharmacological options, this is a promising — if preliminary — signal warranting larger prospective trials.